Genelux Stock (NASDAQ:GNLX)
Previous Close
$2.46
52W Range
$1.60 - $16.60
50D Avg
$2.64
200D Avg
$3.49
Market Cap
$88.07M
Avg Vol (3M)
$179.32K
Beta
-3.17
Div Yield
-
GNLX Company Profile
Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary, modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small-cell lung cancer. The company is also developing V2ACT Immunotherapy for the treatment of pancreatic cancer; and V-VET1 to treat hematologic and solid cancer. The company was incorporated in 2001 and is headquartered in Westlake Village, California.
GNLX Performance
Peer Comparison
Ticker | Company |
---|---|
DYAI | Dyadic International, Inc. |
CGEM | Cullinan Oncology, Inc. |
MNPR | Monopar Therapeutics Inc. |
IVA | Inventiva S.A. |
CNTA | Centessa Pharmaceuticals plc |
IKNA | Ikena Oncology, Inc. |
LRMR | Larimar Therapeutics, Inc. |
DAWN | Day One Biopharmaceuticals, Inc. |
CING | Cingulate Inc. |
TERN | Terns Pharmaceuticals, Inc. |
MLTX | MoonLake Immunotherapeutics |
GLUE | Monte Rosa Therapeutics, Inc. |
ABOS | Acumen Pharmaceuticals, Inc. |
NAMS | NewAmsterdam Pharma Company N.V. |
IMRX | Immuneering Corporation |
CELC | Celcuity Inc. |
CMPX | Compass Therapeutics, Inc. |
AMLX | Amylyx Pharmaceuticals, Inc. |